Opioid-induced Respiratory Depression

• CLINICAL_TRIALS research · 2026-02-09
  Clinical Trial Update: Respiratory Monitoring System That Detects & Predicts OIRD [NA]

  Thomas Jefferson University is conducting a clinical trial of a respiratory monitoring system designed to detect and predict opioid-induced …

• CLINICAL_TRIALS research · 2025-12-30
  Clinical Trial Update: ENA-001 for Opioid Induced Respiratory Depression [Phase 1]

  Phase 1 clinical trial update for ENA-001 evaluating treatment for opioid-induced respiratory depression. The study is active but not recrui…

• CLINICAL_TRIALS research · 2025-01-31
  Clinical Trial Update: Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists [Phase 1]

  Phase 1 clinical trial evaluating reversal of opioid-induced respiratory depression with opioid antagonists; currently recruiting.

• CLINICAL_TRIALS trial_result · 2024-06-04
  Clinical Trial Update: Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing [Phase 4]

  A Phase 4 trial evaluated how combining pregabalin with oxycodone and lacosamide with oxycodone affects breathing in opioid-induced respirat…

• FDA approval · 2022-06-09
  FDA Approved: NALOXONE HYDROCHLORIDE — Original Application (Mylan Institutional LLC)

  FDA approved Naloxone hydrochloride under an Original Application from Mylan Institutional LLC, establishing a generic naloxone product.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2017-07-26
  FDA Approved: NALOXONE HYDROCHLORIDE — Original Application (Somerset Therapeutics, LLC)

  FDA approved the original application for Naloxone Hydrochloride (generic) from Somerset Therapeutics, LLC.

• CLINICAL_TRIALS trial_result · 2016-07-28
  Clinical Trial Update: Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia [Phase 2]

  Phase 2 trial update evaluating CX1739 to reverse opioid-induced respiratory depression while preserving opioid analgesia.

• FDA approval · 2015-03-12
  FDA Approved: NALOXONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

  FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for naloxone hydrochloride, a generic product, under ANDA070299.

• CLINICAL_TRIALS trial_result · 2013-05-23
  Clinical Trial Update: Critical Respiratory Events in Children Requiring Naloxone: Naloxone Use as Opioid Safety Measure

  This completed clinical trial evaluates naloxone use as a safety measure in children with opioid-induced respiratory depression.